MedPath

Phosphocreatine

Generic Name
Phosphocreatine
Drug Type
Small Molecule
Chemical Formula
C4H10N3O5P
CAS Number
67-07-2
Unique Ingredient Identifier
020IUV4N33
Background

Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to regenerate adenosine triphosphate (ATP) from adenosine diphosphate (ADP).

Indication

Phosphocreatine is a naturally occuring substance that is found predominantly in the skeletal muscles of vertebrates. Its primary utility within the body is to serve in the maintanence and recycling of adenosine triphosphate (ATP) for muscular activity like contractions.

Given this utility of phosphocreatine to recycle ATP, the most plausible therapeutic potentials for its use involve conditions caused by energy shortage or by increased energy requirements - such as in ischemic stroke and other cerebrovascular diseases. It is important to note however that relatively little clinical research has been done to significantly further the evidence for any such indications, although it is administered intravenously for cardiovascular conditions in some countries.

Additionally, because phosphocreatine is not regulated as a controlled substance it is taken as a supplement by some professional athletes as a means to perhaps increase short bursts of muscle strength or energy for professional athletics.

Associated Therapies
Cardioprotection

The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients

Phase 3
Recruiting
Conditions
Hypotension
Respiratory Failure
Bradypnea
Bradycardia
Cardiac Failure
Cardiac Arrest
Consciousness, Level Altered
Airway Disease
Tachypnea
Tachycardia
Interventions
First Posted Date
2024-07-16
Last Posted Date
2025-01-28
Lead Sponsor
Università Vita-Salute San Raffaele
Target Recruit Count
400
Registration Number
NCT06503016
Locations
🇮🇹

IRCCS San Raffaele Scientific Institute, Milan, Italy

Rapid Improvement of Depression of Fluoxetine Combined With ATP

Phase 2
Recruiting
Conditions
Depression
First Posted Date
2022-06-24
Last Posted Date
2023-11-15
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
195
Registration Number
NCT05431413
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Rapid Antidepressant Effects of ATP and Phosphocreatine

Phase 2
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2017-05-03
Last Posted Date
2017-05-08
Lead Sponsor
Zhujiang Hospital
Target Recruit Count
42
Registration Number
NCT03138681
Locations
🇨🇳

Zhujiang Hospital, Guangzhou, Guangdong, China

Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients

Phase 3
Completed
Conditions
Cardiac Surgical Procedures
Heart Valve Prosthesis Implantation
Interventions
First Posted Date
2016-05-02
Last Posted Date
2021-07-01
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Target Recruit Count
120
Registration Number
NCT02757443
Locations
🇷🇺

Evgeny Fominskiy, Novosibirsk, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath